Disappointing Prostate Cancer Phase III Results for Cabozantinib.

Exelixis, the biotechnology firm developing the metastatic medullary thyroid cancer drug, cabozantinib, in the treatment of a variety of cancers, recently announced disappointing Phase III clinical trial results for the use of cabozantinib in the treatment of metastatic,  hormone-resistant (refractory) prostate cancer. The drug continues to be clinically evaluated in metastatic renal cell and advanced hepatocellular carcinomas.

1 thought on “Disappointing Prostate Cancer Phase III Results for Cabozantinib.”

Leave a Comment

Your email address will not be published. Required fields are marked *